Welcome to our dedicated page for Centessa Pharmaceuticals news (Ticker: CNTA), a resource for investors and traders seeking the latest updates and insights on Centessa Pharmaceuticals stock.
Centessa Pharmaceuticals plc reports developments as a clinical-stage pharmaceutical company focused on orexin receptor 2 (OX2R) agonists for neuroscience indications. Company news centers on its OX2R pipeline, including preclinical data and therapeutic areas tied to excessive daytime sleepiness, impaired attention, cognitive deficits, fatigue, mood symptoms, and related neurological, neurodegenerative, and neuropsychiatric disorders.
Recurring updates also include investor conference participation, leadership and board governance changes, American Depositary Share offerings, capital-structure activity, material agreements, shareholder voting matters, and operating and financial results for its Nasdaq-listed ADSs.
Summary not available.
Summary not available.
Summary not available.
Transgene (Euronext Paris: TNG) has proposed Carol Stuckley as an independent Director, enhancing its corporate governance with an emphasis on director independence and gender diversity. Stuckley, a seasoned financial executive with over 35 years of experience, is currently a Board Director at Centessa Pharmaceuticals and has held key roles at Ipsen and Galderma North America. This nomination comes after the resignation of Laurence Espinasse. Shareholders will vote on Stuckley's appointment at the General Meeting scheduled for May 5, 2023. If approved, Transgene's Board will consist of 10 members, 6 of whom will be independent, contributing diverse skills aligned with its strategic needs.
HDAX Therapeutics has appointed Dr. Roman Fleck as Executive Chairman and Dr. Neal I. Muni as an independent Board member, enhancing the leadership team's strategic capabilities. Dr. Fleck brings extensive experience from roles at Janpix, Inc. and Medicxi Ventures, while Dr. Muni has over 20 years in the biopharmaceutical sector and is currently the COO of Comera Life Sciences (NASDAQ:CMRA). Both are expected to advance HDAX's development of first-in-class therapies targeting neurological and cardiac diseases linked to microtubule dysfunction, which have significant unmet needs. Their appointments come at a critical juncture for HDAX, as the company aims to leverage its innovative platform technology for potential breakthroughs in treatment.
Centessa Pharmaceuticals (Nasdaq: CNTA) reported significant advancements in 2022, including the initiation of a registration program for SerpinPC to treat hemophilia B and the first subject dosed in a Phase 1/2a trial for LB101, a PD-L1xCD47 bispecific antibody for solid tumors. The company also introduced ORX750, an orexin receptor-2 agonist for narcolepsy. With a strong cash position of $393.6 million, Centessa expects to fund its operations into 2026. R&D expenses decreased, leading to a reduced net loss of $43.2 million in Q4 2022. The ongoing clinical programs and significant cash runway position Centessa for future growth.
Centessa Pharmaceuticals plc (Nasdaq: CNTA) has announced its participation in two upcoming investor conferences:
- Guggenheim Genomic Medicines and Rare Disease Days
Date: April 3, 2023, Location: New York, NY, Fireside Chat: 9:35 AM ET - Jefferies & Venrock Boston Biotech Summit
Date: April 12, 2023
Presentation materials along with live webcasts and archived recordings will be accessible through the investor relations section of Centessa's website. Established to innovate in patient care, Centessa focuses on developing medicines across various stages targeting significant health issues.
Clarivate Plc (NYSE: CLVT) announced the appointment of Gordon Samson as President of its Intellectual Property (IP) market segment, effective April 1, 2023. Previously serving as Chief Product Officer, Samson aims to drive growth in the IP sector. The company also nominated Dr. Saurabh Saha for election to the Board at the Annual General Meeting on May 4, 2023. Dr. Saha, currently CEO of Centessa Pharmaceuticals (NASDAQ: CNTA), brings extensive experience in pharmaceuticals and biotech. This strategic move is to enhance leadership as Clarivate executes its growth strategy in Life Sciences & Healthcare.
Clarivate Plc (NYSE: CLVT) has announced the appointment of Gordon Samson as President of its Intellectual Property market segment, effective April 1, 2023. This new role aims to enhance growth within the IP sector. Additionally, Dr. Saurabh Saha has been nominated for election as an Independent Director at the upcoming 2023 Annual General Meeting on May 4, 2023. Dr. Saha, currently CEO of Centessa Pharmaceuticals (NASDAQ: CNTA), brings extensive experience in the pharmaceutical and biotech fields. Clarivate's CEO, Jonathan Gear, expressed confidence in Samson's ability to drive innovation and growth.
Centessa Pharmaceuticals plc (Nasdaq: CNTA) has appointed Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines. This strategic move comes as the company focuses on advancing key clinical programs, including SerpinPC for hemophilia, LB101 for solid tumors, and MGX292 for pulmonary arterial hypertension. Dr. Yue brings extensive experience from his previous role at Global Blood Therapeutics and is expected to strengthen Centessa's clinical development efforts. The company aims to meet crucial clinical milestones in its pipeline, emphasizing its commitment to transforming patient care.